IPO registrations (S-1, F-1) · Registrants
Altus Pharmaceuticals Inc.
- SEC CIK
- 1340744 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2005-10-17, last 2006-01-25; 1 initial registration, 6 amendments
- Outcome
- Final prospectus filed 2006-01-26; declared effective 2007-04-05
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 610 LINCOLN STREET, Waltham, MA 02451
- EIN
- 04-3573277
- EDGAR entity type
- operating
- Insiders and CEO pay
- Altus Pharmaceuticals Inc. on the corporate pages
Offering terms
- Final price
- $15.00 per share (424B4 filed 2006-01-26, an initial public offering)
- Shares sold
- 7,000,000
- Gross proceeds
- $105,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ALTU
- Lead underwriters
- Merrill Lynch; Morgan Stanley (2,660,000 shares); Cowen (1,330,000 shares)
- Syndicate
- Leerink Partners (87,500); Oppenheimer (87,500); Susquehanna Financial Group, LLLP (87,500); Toussaint Capital Partners, LLC (87,500)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: ALTUS PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- SEC filer: Altus Pharmaceuticals Inc. EXACT (CIK (EXACT))
- Person page: David E Liddle Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2005-10-17 | S-1 | S-1 (registration) | Altus Pharmaceuticals Inc. | 0000950135-05-005771 ↗ |
| 2005-11-02 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-05-006166 ↗ |
| 2005-11-30 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-05-006733 ↗ |
| 2005-12-27 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-05-007137 ↗ |
| 2006-01-11 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-06-000105 ↗ |
| 2006-01-23 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-06-000247 ↗ |
| 2006-01-25 | S-1/A | S-1/A (amendment) | Altus Pharmaceuticals Inc. | 0000950135-06-000307 ↗ |
| 2006-01-25 | S-1MEF | S-1MEF (added securities) | Altus Pharmaceuticals Inc. | 0000950135-06-000320 ↗ |
| 2006-01-26 | 424B4 | 424B4 (final prospectus) | Altus Pharmaceuticals Inc. | 0000950135-06-000323 ↗ |
| 2007-04-05 | EFFECT | EFFECT (declared effective) | Altus Pharmaceuticals Inc. | 9999999995-07-001246 ↗ |
Prospectus pages read 3
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2006-01-23 | S-1/A | registration statement | $4.31 | 11,819,959 | $50,944,023 | 0 | primary document; price line, shares headline, proceeds computed | document ↗ | ||
| 2006-01-25 | S-1/A | registration statement | - | - | 0 | primary document; no terms found | document ↗ | |||
| 2006-01-26 | 424B4 | final prospectus | $15.00 | 7,000,000 | $105,000,000 | Nasdaq ALTU | 7 | primary document; price sentence, shares headline, proceeds table, underwriting table 6 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| ALDRICH RICHARD | Director | 1 | 2006 | ||
| Berkle Sheldon | Director,Officer | President and CEO | 14 | 2006–2007 | |
| BRUM LYNNE H | Director | 2 | 2006 | ||
| Burstyn Don G | Officer | VP, Reg. Affairs & Qual. Assur | 1 | 2006 | |
| Connors Timothy J | TenPercentOwner | 3 | 2006–2009 | ||
| FEDERMAN IRWIN | TenPercentOwner | 3 | 2006–2009 | ||
| Forrest Richard D | Officer | Corporate Counsel & Secretary | 1 | 2006 | |
| FU WINSTON S | TenPercentOwner | 3 | 2006–2009 | ||
| Gallotto Robert | Officer | VP, Strategic Planning | 17 | 2006–2008 | |
| HEN STEWART | Director; Director,TenPercentOwner | 6 | 2006–2008 | ||
| Kimura Alan | Officer | VP, Clinical Development | 1 | 2006 | |
| Klement Gerhard F | Officer | VP, Manufacturing & Tech. Op. | 1 | 2006 | |
| KRAUSZ STEVEN M | TenPercentOwner | 3 | 2006–2009 | ||
| Lanciano Peter L | Director | 1 | 2006 | ||
| LEFF JONATHAN S | Director; Director,TenPercentOwner | 6 | 2006–2008 | ||
| LIDDLE DAVID E | TenPercentOwner | 3 | 2006–2009 | person page Fuzzy | |
| Lieber Jonathan I | Officer | SVP, CFO and Treasurer; VP, CFO and Treasurer | 14 | 2006–2008 | |
| Margolin Alexey L | Officer | Chief Scientific Officer | 16 | 2006–2007 | |
| NAVIA MANUEL | Director | 6 | 2006–2009 | ||
| PRESIDIO MANAGEMENT GROUP VIII L L C | TenPercentOwner | 6 | 2006–2009 | ||
| Richard John P | Director | 8 | 2006–2009 | ||
| ROOT JONATHAN D | Director,TenPercentOwner; TenPercentOwner | 7 | 2006–2009 | ||
| Rust Christopher J | TenPercentOwner | 3 | 2006–2009 | ||
| US VENTURE PARTNERS VIII L P | TenPercentOwner | 3 | 2006–2009 | ||
| USVP ENTREPRENEUR PARTNERS VIII A L P | TenPercentOwner | 3 | 2006–2009 | ||
| USVP ENTREPRENEUR PARTNERS VIII B L P | TenPercentOwner | 3 | 2006–2009 | ||
| USVP VIII AFFILIATES FUND L P | TenPercentOwner | 3 | 2006–2009 | ||
| VERTEX PHARMACEUTICALS INC / MA | TenPercentOwner | 3 | 2006 | ||
| WARBURG PINCUS PRIVATE EQUITY VIII L P | TenPercentOwner | 5 | 2006–2009 | ||
| WYZGA MICHAEL S | Director | 6 | 2006–2009 | ||
| YOUNG PHILIP M | TenPercentOwner | 3 | 2006–2009 | ||
| NOMURA INTERNATIONAL PLC | Other; TenPercentOwner | 4 | 2006 | ||
| Nomura Phase4 Ventures LP | Other; TenPercentOwner | 4 | 2006 | ||
| WARBURG PINCUS & CO | TenPercentOwner | 5 | 2006–2009 | ||
| WARBURG PINCUS LLC | TenPercentOwner | 5 | 2006–2009 | ||
| Warburg Pincus Partners LLC | TenPercentOwner | 5 | 2006–2009 | ||
| PENNER HARRY JR | Director | 7 | 2006–2009 | ||
| Sabella Lauren M | Officer | VP of Commercial Development | 4 | 2006–2008 | |
| BLANK BURKHARD | Officer | EVP & Chief Medical Officer; SVP, Med., Reg Aff. & Proj Mgt | 6 | 2006–2008 | |
| Sorvillo John M | Officer | VP, Business Development | 4 | 2006–2008 | |
| FUCHS RENATO | Officer | SVP, Manufacturing & Tech Ops | 4 | 2006–2007 | |
| Nomura Phase4 Ventures GP LTD | Other; TenPercentOwner | 2 | 2006 | ||
| Nomura Phase4 Ventures LTD | Other; TenPercentOwner | 2 | 2006 | ||
| PENDERGAST DAVID D PHD | Director; Director,Officer | Executive Chairman | 8 | 2006–2009 | |
| Leicher Bruce | Officer | Sr VP Gen Counsel & Secretary | 3 | 2006–2008 | |
| Gotwals Philip | Officer | VP of Project Management; VP, Program Management | 4 | 2007–2009 | |
| GEMAYEL GEORGES | Director,Officer | President & CEO | 5 | 2008–2009 | |
| Attie Kenneth | Officer | VP, Clinical Dev & Med Affairs | 2 | 2009 | |
| Phair Thomas J. | Officer | Sr. Dir, Finance & Controller | 2 | 2009 | |
| Porter Jill | Officer | VP, Process Dev & Engineering | 2 | 2009 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | Altus Pharmaceuticals Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Altus Pharmaceuticals Inc. | MA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | ALTUS PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | David E Liddle | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MA first:
- TRANSCEND THERAPEUTICS INC MA
- Eloxx Pharmaceuticals, Inc. MA
- PANACOS PHARMACEUTICALS, INC. MA
- CHARLES RIVER LABORATORIES INC MA
- AGENUS INC MA
- CURIS INC MA
- MOMENTA PHARMACEUTICALS INC MA
- ACCELERON PHARMA INC MA
- bluebird bio, Inc. MA
- BioVex Group, Inc. MA
In other datasets, the same topic (Health) in MA:
- Nonprofit: ABBIE M GRIFFIN HOSPITAL FUND (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health